Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib

21.11.2023 - The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21, 2023: Pharming Group N.V. ... Seite 1

Related Keywords

Japan ,Eveline Wu ,University Of North Carolina School Medicine ,Division Chief ,Paediatric Rheumatology ,Associate Professor ,North Carolina School ,Pharming Group Aktie ,